Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Pipeline Review, H2 2018

Publisher Name :
Date: 11-Sep-2018
No. of pages: 79

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Pipeline Review, H2 2018

Summary

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Connective Tissue Growth Factor - Pipeline Review, H2 2018, outlays comprehensive information on the Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Connective tissue growth factor (CTGF), also known as CCN2 is a matricellular protein of the CCN family of extracellular matrix-associated heparin-binding proteins. CTGF plays an important role in promoting fibroblast proliferation, migration, adhesion, and extracellular matrix formation, and its overproduction plays a major role in pathways that lead to fibrosis (TGF-beta-dependent). This includes fibrosis of major organs, fibroproliferative diseases, and scarring.

CTGF also plays an important role in the extracellular matrix remodeling that occurs in normal physiological processes such as embryogenesis, implantation, and wound healing. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Genetic Disorders, Oncology, Respiratory, Dermatology, Metabolic Disorders, Musculoskeletal Disorders, Cardiovascular, Genito Urinary System And Sex Hormones, Immunology and Toxicology which include indications Liver Fibrosis, Idiopathic Pulmonary Fibrosis, Diabetic Nephropathy, Duchenne Muscular Dystrophy, Fibrosis, Hypertrophic Scars, Non-Alcoholic Steatohepatitis (NASH), Acute Lung Injury, Chronic Kidney Disease (Chronic Renal Failure), Cirrhosis, Fatty Liver Disease, Keloids, Kidney Fibrosis, Liver Cancer, Metabolic Syndrome, Myocardial Fibrosis, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Scar and Systemic Sclerosis (Scleroderma).

Furthermore, this report also reviews key players involved in Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF)

- The report reviews Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics and enlists all their major and minor projects

- The report assesses Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Overview
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Companies Involved in Therapeutics Development
BLR Bio LLC
FibroGen Inc
OliX Pharmaceuticals Inc
ProMetic Life Sciences Inc
RXi Pharmaceuticals Corp
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Drug Profiles
BLR-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLR-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target SOD2 and CTGF for Radiation Toxicity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-DMD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-301D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pamrevlumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-4050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Dormant Products
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Discontinued Products
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Product Development Milestones
Featured News & Press Releases
Aug 10, 2018: Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in journal of pharmacology and experimental therapeutics
Aug 07, 2018: Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050
Aug 02, 2018: RXi Pharmaceuticals granted patents for sd-rxRNA technology strengthening intellectual property estate in Europe and Japan
Aug 01, 2018: RXi Pharmaceuticals announces positive results from phase 1/2 trial with RXI-109 For retinal scarring
Jun 03, 2018: FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting
May 29, 2018: OliX Pharmaceuticals receives Clinical Trial Authorization in the UK to initiate Phase I study with OLX10010, an anti-scar RNAi therapeutics
May 22, 2018: Prometic presents new clinical data on PBI-4050 for the treatment of idiopathic pulmonary fibrosis
May 21, 2018: FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018
May 08, 2018: RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO
Apr 12, 2018: Prometic Presents New PBI-4050 Clinical Data From Ongoing Alstrom Syndrome Phase 2 Trial
Apr 04, 2018: RXi Pharmaceuticals to Present an Update on its Hypertrophic Dermal Scars Drug Candidate RXI-109 at the International Investigative Dermatology Conference
Mar 28, 2018: Prometic Reports Positive Clinical Data From Ongoing PBI-4050 Phase 2 Study in Alstrom Syndrome Patients
Mar 01, 2018: Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer
Feb 16, 2018: Prometic Announces Publication of PBI-4050's Novel Antifibrotic Mechanism of Action in American Journal of Pathology
Jan 29, 2018: Prometics PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by BLR Bio LLC, H2 2018
Pipeline by FibroGen Inc, H2 2018
Pipeline by OliX Pharmaceuticals Inc, H2 2018
Pipeline by ProMetic Life Sciences Inc, H2 2018
Pipeline by RXi Pharmaceuticals Corp, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global HPV Therapeutic Vaccines Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 109
    Human papilloma virus (HPV) vaccines are used to protect against HPV infections. Human Papillomaviruses (HPV) are members of papillomaviridae family a group of more than 150 related viruses. These are specifically known as papillomaviruses because of some of its types give rise to a wart or papilloma which are benign growths. Some of them are also associated with certain cancers and known as carcinogenic HPVs. Scope of the Report: This report focuses on the ......
  • Global Human Chorionic Gonadotropin (HCG) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 117
    Human chorionic gonadotropin (HCG) is a female hormone produced by the placenta after implantation of the egg, which is why it can be detected in a few pregnancy tests. In addition, it can be extracted from the urine of pregnant women or produced from cultures of genetically modified cells using recombinant DNA technology. Scope of the Report: This report focuses on the Human Chorionic Gonadotropin (HCG) in global market, especially in North America, Europe and Asi......
  • Global Imatinib Drug Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 120
    Imatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases. Scope of the Report: This report focuses on the Imatinib Drug in global market, especially in North America, Europe and A......
  • 2018-2023 Global Novel Drug Delivery Systems Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 184
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Novel Drug Delivery Systems market for 2018-2023. Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a......
  • 2018-2023 Global Non-Radioactive Nucleic Acid Labeling Product Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 135
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Non-Radioactive Nucleic Acid Labeling Product market for 2018-2023. In recent years, non-radioactive nucleic acid labeling and detection methodologies have become available in response to a desire by researchers and their institutions to move away from the use of radioisotopes. Advancements made in the areas of chemiluminescence and fluorescence have allowe......
  • 2018-2023 Global mRNA Vaccines & Therapeutics Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 136
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global mRNA Vaccines & Therapeutics market for 2018-2023. mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensu......
  • 2018-2023 Global Compounding Pharmacy Market Report (Status and Outlook)
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 130
    In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Compounding Pharmacy market for 2018-2023. The traditional role of compounding pharmacies is to make drugs prescribed by doctors for specific patients with needs that can't be met by commercially available drugs. For example: A young child may need a small, liquid dose of a drug made only in adult-dosage tablets. A person may be allergic to o......
  • 2018-2023 Global Eucalyptus Oil Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 161
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Eucalyptus Oil market for 2018-2023. Eucalyptus oil is the generic name for distilled oil from the leaf of Eucalyptus, a genus of the plant family Myrtaceae native to Australia and cultivated worldwide. Eucalyptus oil is one of the most common and widely used essential oils and has a good health care effect. It is colorless or slightly yellow liquid.......
  • 2018-2023 Global Self-Monitoring Blood Glucose (SMBG) Devices Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 138
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Self-Monitoring Blood Glucose (SMBG) Devices market for 2018-2023. Self-monitoring of blood glucose (SMBG) is an important component of modern therapy for diabetes mellitus. SMBG has been recommended for people with diabetes and their health care professionals in order to achieve a specific level of glycemic control and to prevent hypoglycemia. The goal of ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs